The estimated Net Worth of Ricky Hopson is at least $2.89 Milión dollars as of 2 August 2024. Mr Hopson owns over 662 units of Catalent stock worth over $1,787,350 and over the last 3 years he sold CTLT stock worth over $1,106,700.
Mr has made over 12 trades of the Catalent stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 662 units of CTLT stock worth $39,429 on 2 August 2024.
The largest trade he's ever made was selling 2,325 units of Catalent stock on 31 January 2022 worth over $240,382. On average, Mr trades about 870 units every 79 days since 2021. As of 2 August 2024 he still owns at least 29,974 units of Catalent stock.
You can see the complete history of Mr Hopson stock trades at the bottom of the page.
Ricky Hopson is the VP & Chief Accounting Officer at Catalent.
Mr Hopson is 45, he's been the VP & Chief Accounting Officer of Catalent since . There are 25 older and 2 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
Ricky's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius a Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: